Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PMA and doxorubicin decrease viability, MTT activity and expression of CD10 marker on NALM-1 leukemic cells.

I Martin-Kleiner1, I Svoboda-Beusan, J Gabrilovac

  • 1Division of Molecular Medicine, Ruder Bosković Institute, Zagreb, Croatia. kleiner@irb.hr

Immunopharmacology and Immunotoxicology
|September 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro antiproliferative study of novel adamantyl pyridin-4-ones.

Molecular diversity·2017
Same author

Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.

European journal of medicinal chemistry·2014
Same author

Opioid system genes in alcoholism: a case-control study in Croatian population.

Neuropeptides·2013
Same author

Differential expression of proopiomelanocortin (POMC) transcriptional variants in human skin cells.

Neuropeptides·2012
Same author

Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.

European journal of medicinal chemistry·2012
Same author

Selective cytotoxicity of diazenecarboxamides towards human leukemic cell lines.

Toxicology in vitro : an international journal published in association with BIBRA·2007
Same journal

Correction.

Immunopharmacology and immunotoxicology·2026
Same journal

Immuno-regulatory effects of hydroxychloroquine in experimental autoimmune thyroiditis.

Immunopharmacology and immunotoxicology·2026
Same journal

From the lab to the feed: science communication through an immunological lens in the social media era.

Immunopharmacology and immunotoxicology·2026
Same journal

Systemic administration of interleukin-10 is associated with dose-dependent toxicities in Wistar albino rats.

Immunopharmacology and immunotoxicology·2026
Same journal

Nano-enabled strategies for enhancing cancer immunotherapy: challenges, progress and perspective.

Immunopharmacology and immunotoxicology·2026
Same journal

Statement of Retraction: Amygdalin Induces Apoptosis in Human Cervical Cancer Cell Line HeLa Cells.

Immunopharmacology and immunotoxicology·2026
See all related articles

Phorbol 12-myristate 13-acetate (PMA) and doxorubicin reduce viability and induce partial differentiation in NALM-1 leukemic cells by downregulating CD10. These findings offer new insights into leukemia treatment strategies.

Area of Science:

  • * Hematology
  • * Cell Biology
  • * Cancer Research

Background:

  • * Pre-B acute lymphoblastic leukemia (ALL) is a significant hematologic malignancy.
  • * Understanding cellular differentiation pathways is crucial for developing targeted therapies.
  • * NALM-1 cells are a relevant model for studying pre-B ALL progression and treatment responses.

Purpose of the Study:

  • * To investigate the effects of Phorbol 12-myristate 13-acetate (PMA) and doxorubicin on NALM-1 cell viability and differentiation.
  • * To determine the impact of these agents on specific cell surface markers, including CD10, CD20, and mIgM.
  • * To compare the differentiation-inducing effects of PMA with another agent, ATRA (all-trans retinoic acid).

Main Methods:

  • * Treatment of NALM-1 pre-B leukemic cells with varying concentrations of PMA and doxorubicin for 3 days.

Related Experiment Videos

  • * Assessment of cell viability and MTT activity.
  • * Analysis of cell surface marker expression (CD10, CD20, mIgM) using flow cytometry or similar techniques.

    • Main Results:

    • * PMA and doxorubicin significantly decreased NALM-1 cell viability and MTT activity.
    • * Both agents led to the downregulation of CD10 expression, indicating partial cellular differentiation.
    • * PMA did not affect CD20 or mIgM expression, while ATRA impacted viability but not CD10 expression.

    Conclusions:

    • * PMA and doxorubicin demonstrate efficacy in inhibiting NALM-1 leukemic cell growth and inducing partial differentiation.
    • * The downregulation of CD10 is a key indicator of PMA- and doxorubicin-induced differentiation in this cell line.
    • * These findings provide novel evidence for the therapeutic potential of PMA and doxorubicin in targeting pre-B ALL.